Novotech Acquires European CRO EastHORN

Novotech has purchased EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. Neither company disclosed the deal’s terms.

Part of Novotech’s global expansion program, the acquisition enables biotech clients to access Novotech’s suite of early to late-phase contract research organization (CRO) services across Europe and the United States, with a specialist focus on Asia Pacific.
 
“This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global development programs, Novotech CEO Dr. John Moller said. “EastHORN and Novotech have been working together for many years and we share a culture of clinical excellence in biotech development. EastHORN, which is retaining its brand, is now a Novotech company and will be integrated into our systems and processes so clients benefit from working with one CRO globally. Clients can now access our European infrastructure, local knowledge. site relationships, and access to diverse patient populations.”

Established in 2004, EastHORN employs more than 250 people.
 
“I first started working on clinical projects with Novotech 15 years ago and have always been impressed by the quality of their services and their client-focused approach. EastHORN has been working closely with Novotech for over a decade now and have many friends within the Novotech team. This is a natural next step for our group and my colleagues and I are excited to become part of Novotech’s global operations to support biotech clients’ clinical programs,” EastHORN Executive Chairman Iain Gordon said. “In particular, we can now offer our clients access to Novotech’s team of experts across Asia-Pacific and the U.S., including project management, regulatory, clinical, medical, and biometrics, while our team’s European expertise can advance clinical development in Europe for Novotech clients. We work with similar-sized biotechs and small to mid-size companies and have experience across the same therapeutic areas, so this is an excellent cultural and strategic fit.”
 
Novotech is an Asia-Pacific centred biotech CRO. The company has decades of biotech development experience, solid site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. In Asia Pacific, Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions, which delivers exclusive benefits for sponsors.